Shanghai Shyndec Pharmaceutical (600420) Stock Overview
Shanghai Shyndec Pharmaceutical Co., Ltd. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
600420 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Shanghai Shyndec Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥10.80 |
| 52 Week High | CN¥11.80 |
| 52 Week Low | CN¥9.69 |
| Beta | 0.33 |
| 1 Month Change | 1.98% |
| 3 Month Change | 1.03% |
| 1 Year Change | -7.06% |
| 3 Year Change | 5.06% |
| 5 Year Change | 25.29% |
| Change since IPO | 554.67% |
Recent News & Updates
Recent updates
We Ran A Stock Scan For Earnings Growth And Shanghai Shyndec Pharmaceutical (SHSE:600420) Passed With Ease
Mar 14
Is Shanghai Shyndec Pharmaceutical (SHSE:600420) Using Too Much Debt?
Dec 12Here's Why We Think Shanghai Shyndec Pharmaceutical (SHSE:600420) Is Well Worth Watching
Nov 17Shanghai Shyndec Pharmaceutical Co., Ltd. (SHSE:600420) Shares Fly 35% But Investors Aren't Buying For Growth
Oct 08Is Shanghai Shyndec Pharmaceutical (SHSE:600420) Using Too Much Debt?
Aug 23Improved Earnings Required Before Shanghai Shyndec Pharmaceutical Co., Ltd. (SHSE:600420) Stock's 33% Jump Looks Justified
May 06Is Shanghai Shyndec Pharmaceutical (SHSE:600420) A Risky Investment?
Apr 30Solid Earnings May Not Tell The Whole Story For Shanghai Shyndec Pharmaceutical (SHSE:600420)
Apr 05Shareholder Returns
| 600420 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 2.7% | 3.2% | 3.1% |
| 1Y | -7.1% | 17.4% | 30.0% |
Return vs Industry: 600420 underperformed the CN Pharmaceuticals industry which returned 17.4% over the past year.
Return vs Market: 600420 underperformed the CN Market which returned 30% over the past year.
Price Volatility
| 600420 volatility | |
|---|---|
| 600420 Average Weekly Movement | 1.7% |
| Pharmaceuticals Industry Average Movement | 4.2% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in CN Market | 9.7% |
| 10% least volatile stocks in CN Market | 3.1% |
Stable Share Price: 600420 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 600420's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 11,472 | Yong Liu | www.shyndec.com |
Shanghai Shyndec Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in China. The company offers 6-APA, potassium clavulanate series, diclofenac sodium extended release tablets, urine-derived biochemical products, nifedipine controlled release tablets, azithromycin, ceftriaxone sodium for injection, methylprednisolone sodium succinate for injection, cefuroxime tablets/capsules, ampicillin acid, penicillin industrial potassium salt, Touboke Yuekui granules/capsules, remifentanil hydrochloride for injection, sodium cefuroxime for injection, ceftriaxone sodium crude salt, D-7ACA, fermented products, milnacipran hydrochloride tablets, compound licorice tablets, 7-ACA, amlodipine besylate tablets, cefoperazone dispersible tablets, and amoxicillin capsules. Shanghai Shyndec Pharmaceutical Co., Ltd.
Shanghai Shyndec Pharmaceutical Co., Ltd. Fundamentals Summary
| 600420 fundamental statistics | |
|---|---|
| Market cap | CN¥14.48b |
| Earnings (TTM) | CN¥944.38m |
| Revenue (TTM) | CN¥9.36b |
Is 600420 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 600420 income statement (TTM) | |
|---|---|
| Revenue | CN¥9.36b |
| Cost of Revenue | CN¥0 |
| Gross Profit | CN¥9.36b |
| Other Expenses | CN¥8.42b |
| Earnings | CN¥944.38m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Mar 28, 2026
| Earnings per share (EPS) | 0.70 |
| Gross Margin | 100.00% |
| Net Profit Margin | 10.09% |
| Debt/Equity Ratio | 0.3% |
How did 600420 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/10 18:02 |
| End of Day Share Price | 2026/02/10 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Shanghai Shyndec Pharmaceutical Co., Ltd. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sophia Zhang | China Stock Investment Research Co. Ltd. (GZ500..com) |
| Yanpeng Xu | Guosen Securities Co., Ltd. |
| null Research Department | Guotai Junan International Holdings Limited |